Human Trials

Pfizer halts two trials of DMD drug domagrozumab

Pfizer said that it is terminating two ongoing trials - B5161002, a phase 2 safety and efficacy study and B5161004, an open-label extension study, which are assessing domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).

Sonoma Pharmaceuticals’ HOCI demonstrates positive effect in acne study

Sonoma Pharmaceuticals has announced the results from a study, which assessed the use of its proprietary high-strength performance-stabilized HOCl (Hypochlorous Acid) in the management of acne vulgaris.

MXC gets approval for phase 2 trial of marijuana-based CogniCann in dementia

MGC Pharmaceuticals (MXC) has secured a key approval in Australia to launch a phase 2 trial to evaluate CogniCann, a medicinal cannabis compounded formulation, as a potential treatment of mild Dementia and Alzheimer’s.

AstraZeneca’s COPD treatment Bevespi Aerosphere fails in phase IIIb trial

AstraZeneca’ Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has failed to demonstrate superiority against umeclidinium/vilanterol in treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the phase IIIb trial.

Pfizer, Astellas amend clinical research protocols for two phase 3 trials of Enzalutamide

Pfizer and Astellas Pharma have announced amendments to the protocols for two registrational phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).

Can-Fite enrolls first patient in phase 3 trial of Piclidenoson in psoriasis

Can-Fite BioPharma has enrolled and dosed the first patient in its phase 3 Comfort trial to evaluate its small orally bioavailable drug Piclidenoson (CF101) for the treatment of moderate-to-severe plaque psoriasis.

Rexahn partners with Merck on combo study in TNBC

Merck has signed a clinical trial collaboration agreement with Rexahn Pharmaceuticals to assess the combination of RX-5902 (Supinoxin) and Keytruda (pembrolizumab) in a breast cancer trial.

Sensorion secures approval to start SENS-401 phase 2 trial in sudden sensorineural hearing loss

The Heads of Medicines Agencies (HMA), a European network of the heads of the national competent authorities, has approved Sensorion's volunturary harmonization procedure (VHP) application to initiate a phase 2 trial for SENS-401 for the treatment of sudden sensorineural hearing loss (SSNHL) in adults.

AC Immune reports clinical milestones for ACI-24 vaccine in Alzheimer’s disease and Down Syndrome

Swiss clinical-stage biopharmaceutical firm AC Immune has announced two clinical milestone events related to ACI-24, its anti-Abeta vaccine against Alzheimer's disease and Abeta-related cognitive decline in Down Syndrome.